+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alcoholic Hepatitis Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Alcoholic Hepatitis Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4792944
  • Report
  • June 2019
  • Region: Global
  • 114 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Apotex Inc.
  • Gilead Sciences Inc.
  • Novartis AG
  • MORE
Global Alcoholic Hepatitis Treatment Market: About this market

Alcoholic hepatitis is inflammation of the liver, which is caused due to the heavy drinking of alcohol. This alcoholic hepatitis treatment market analysis considers sales from different types of treatments, including corticosteroids, xanthine derivatives, and others. Our analysis also considers the sales of alcoholic hepatitis treatment in Asia, Europe, North America, and ROW. In 2018, the corticosteroids segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the development of combination therapies will play a significant role in the corticosteroids segment to maintain its market position. Also, our global alcoholic hepatitis treatment market report looks at factors such as the increasing consumption of alcohol worldwide, availability of prognostic models for alcoholic hepatitis, and high market penetration of corticosteroids and off-label therapies. However, lack of therapies to treat severe alcoholic hepatitis, side effects associated with drugs used to treat alcoholic hepatitis, and availability of alternative therapies may hamper the growth of the alcoholic hepatitis treatment industry over the forecast period.

Global Alcoholic Hepatitis Treatment market: Overview

Increasing consumption of alcohol worldwide

Heavy alcohol consumption leads to hepatic encephalopathy and high mortality rates. This has created an opportunity for vendors to launch off-label therapies and corticosteroids in the market. The increasing demand for these drugs will lead to the expansion of the global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period.

Development of novel targets and viable treatment options for the management of alcoholic hepatitis

Vendors are heavily investing in the development of novel targets and viable treatment options due to the lack of effective treatments for severe alcoholic hepatitis. Also, certain novel drugs developed by them are under clinical trials. This further creates growth opportunities for vendors, which is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global alcoholic hepatitis treatment market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alcoholic hepatitis treatment manufacturers, that include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd.

Also, the alcoholic hepatitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apotex Inc.
  • Gilead Sciences Inc.
  • Novartis AG
  • MORE

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Corticosteroids - Market size and forecast 2018-2023
  • Xanthine derivatives - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Development of combination therapies to treat severe alcoholic hepatitis
  • Development of novel targets and viable treatment options for management of alcoholic hepatitis
  • Research for development of drugs that act against alcohol dependence

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Apotex Inc.
  • Gilead Sciences Inc.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

List of Exhibits:
Exhibit 01: Global metabolic disorder therapeutics market
Exhibit 02: Segments of global metabolic disorder therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 21: Xanthine derivatives - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Xanthine derivatives - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Novel drugs under development for alcoholic hepatitis
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Apotex Inc. - Vendor overview
Exhibit 47: Apotex Inc. - Key offerings
Exhibit 48: Gilead Sciences Inc. - Vendor overview
Exhibit 49: Gilead Sciences Inc. - Business segments
Exhibit 50: Gilead Sciences Inc. - Organizational developments
Exhibit 51: Gilead Sciences Inc. - Geographic focus
Exhibit 52: Gilead Sciences Inc. - Key offerings
Exhibit 53: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 54: Johnson & Johnson Services, Inc. - Business segments
Exhibit 55: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 56: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 57: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 58: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 59: Novartis AG - Vendor overview
Exhibit 60: Novartis AG - Business segments
Exhibit 61: Novartis AG - Organizational developments
Exhibit 62: Novartis AG - Geographic focus
Exhibit 63: Novartis AG - Segment focus
Exhibit 64: Novartis AG - Key offerings
Exhibit 65: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 66: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 67: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 68: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 69: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 70: Validation techniques employed for market sizing
Exhibit 71: Definition of market positioning of vendors

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Apotex Inc.
  • Gilead Sciences Inc.
  • Novartis AG
  • MORE
The following companies are recognised as the key players in the global alcoholic hepatitis treatment market: Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel targets and viable treatment options for the management of alcoholic hepatitis.”

According to the report, one of the major drivers for this market is the increasing consumption of alcohol worldwide.

Further, the report states that one of the major factors hindering the growth of this market is the availability of alternative therapies.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Apotex Inc.
  • Gilead Sciences Inc.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll